Login    Join free Add to favorites    中文
home > news > SIRION Biotech and Acucela Set Sights on Gene Delivery Tools for Ocular Gene Therapy
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
SIRION Biotech and Acucela Set Sights on Gene Delivery Tools for Ocular Gene Therapy

hits:187     Date:01/09/18
MUNICH, GERMANY (January 8, 2018)SIRION Biotech GmbH (鈥淪IRION鈥), a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced today that it signed a two year development agreement with Acucela Inc. (鈥淎cucela鈥), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy. With this cooperative effort, Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa (RP). Key terms of the agreement include milestone payments to SIRION, with additional royalties to be paid on net sales from resulting products or therapies.
 
RP is the most common form of inherited retinal degeneration. Onset is usually in childhood and progresses to complete blindness by around age 40. It is estimated that approximately 1 in 4000 people are affected in their lifetime(1), and approximately 1.5 million people worldwide are affected by the disease(2). RP describes a family of slowly progressing diseases that are caused by a variety of autosomal dominant, autosomal recessive and x-linked mutations that lead to photoreceptor degeneration. It is a complex indication with over 100 pathogenic mutations identified(3). To date, no pharmacological treatment is available.
 
Recombinant adeno associated virus (rAAV) vectors are considered the best and most promising gene delivery system for therapeutic applications and have been shown in preclinical experiments to successfully deliver human rhodopsin (hRho) to the retina. Acucela, together with SIRION and an academic partner consortium, aims to develop the next generation of rAAV vectors. The goal is to secure new and modified AAV capsids that will ensure that the therapeutic viral particles exhibit a safe product profile with improved specificity for therapeutic protein delivery, over wild type vectors, that is needed to effectively restore light sensitivity to patients.
SIRION relies on 10 years of experience in viral vector engineering and leverages close ties to leading academics in Europe that will play a pivotal role in this project. World renowned experts in AAV biology, Prof. Grimm from the Unversitätsklinikum Heidelberg and Prof. B眉ning of the Medizinische Hochschule Hannover as well as PD Dr. Michalakis from the Ludwig-Maximilians-Universität M眉nchen will contribute their individual expertise to this program.
 
鈥淭he academic acumen of our partners, together with our strong viral vector specialization and experience will empower our client to enter clinical trials with an efficient, safe and scalable product. For us it is the chance to participate in a fundamental step for gene therapies that can help millions of patients worldwide win back their eyesight. This is what we started SIRION Biotech for,鈥 said Dr. Christian Thirion, founder and CEO of the company.
 
Additionally, Dr. Ryo Kubota, MD, PhD, Chairman, President and CEO of Acucela stated, 鈥淲e are pleased to advance our optogenetic genetherapy program in partnership with SIRION Biotech to bring a new therapeutic approach to RP patients suffering from this devastating disease.鈥
 
(1) Genetics Home Reference, retinitis pigmentosa. https://ghr.nlm.nih.gov/condition/retinitis-pigmentosa. Retrieved Nov 7, 2016.
(2) Vaidya P, Vaidaya A. Retinitis Pigmentosa: Disease Encumbrance in the Eurozone. Int J Ophthalmol Clin Res. 2:030 (2015).
(3) National Human Genome Research Institute. Leaning About Retinitis Pigmentosa. https://www.genome.gov/13514348/. Retrieved Nov 7, 2016.
 
About SIRION Biotech GmbH
SIRION Biotech provides custom engineering services of viral vector strategies for research and development in the life sciences and industry. The Germany-based technology expert provides small to large-scale projects to customers worldwide, over 200 a year. SIRION Biotech's unique focus on gene delivery is why it is the only company able to master customization of all three major virus systems that are used regularly for therapeutic and research purposes, to genetically modify mammalian cells. The company has a strong customer base in cancer research, neurosciences, regenerative medicines, gene therapy and immuno-oncology. www.sirion-biotech.com
 
About Acucela Inc.
Acucela Inc., is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela鈥檚 development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataracts and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients. http://www.acucela.com; http://www.kubotaholdings.co.jp/en/
 
Contact SIRION:
SIRION Biotech GmbH
Dr. Christian Thirion
Founder and CEO
Phone: +49-89-700 961 99-15
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙